Form 4: KalVista Pharmaceuticals Officer Reports Stock Transactions

Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, reports the acquisition and disposal of company stock and restricted stock units.

Summary

• On February 22, 2025, Paul K. Audhya, the Chief Medical Officer of KalVista Pharmaceuticals, exercised restricted stock units (RSUs) to acquire 5,000 shares of common stock.
• Also on February 22, 2025, Audhya was granted 100,000 restricted stock units.
• On February 24, 2025, Audhya sold 2,394 shares of common stock at a price of $10.02 per share.
• The sale was to cover tax withholding obligations related to the vesting and settlement of RSUs.
• Following these transactions, Audhya directly owns 102,940 shares of KalVista Pharmaceuticals common stock and 65,000 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company officer. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased number of shares in the market, but the impact is likely to be minimal given the relatively small number of shares involved.

Key Dates